Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - Deferred ChargesAmortization - IntangiblesConsolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Verastem (VSTM) Research & Development: 2018-2025

Historic Research & Development for Verastem (VSTM) over the last 8 years, with Sep 2025 value amounting to $29.0 million.

  • Verastem's Research & Development rose 17.11% to $29.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $103.7 million, marking a year-over-year increase of 39.30%. This contributed to the annual value of $81.3 million for FY2024, which is 32.56% up from last year.
  • Per Verastem's latest filing, its Research & Development stood at $29.0 million for Q3 2025, which was up 16.96% from $24.8 million recorded in Q2 2025.
  • In the past 5 years, Verastem's Research & Development registered a high of $29.2 million during Q1 2025, and its lowest value of $8.9 million during Q1 2021.
  • Moreover, its 3-year median value for Research & Development was $19.4 million (2024), whereas its average is $20.3 million.
  • In the last 5 years, Verastem's Research & Development dropped by 18.56% in 2021 and then soared by 77.50% in 2024.
  • Over the past 5 years, Verastem's Research & Development (Quarterly) stood at $11.4 million in 2021, then decreased by 5.76% to $10.7 million in 2022, then grew by 23.55% to $13.9 million in 2023, then spiked by 77.50% to $20.8 million in 2024, then increased by 17.11% to $29.0 million in 2025.
  • Its Research & Development was $29.0 million in Q3 2025, compared to $24.8 million in Q2 2025 and $29.2 million in Q1 2025.